RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

Black and American Indian patients are less likely to have elevated cancer antigen (CA)-125 levels at ovarian cancer ...

Researchers examined CA-125 levels at diagnosis, defining them as elevated/borderline or negative/normal in 250,749 patients ...

Preclinical highlights： EVM14 induced a dose-dependent, antigen-specific immune response in mice and significantly inhibited tumor growth in multiple syngeneic tumor models. As a therapeutic ...

Researchers are warning that men who regularly dodge prostate cancer screening appointments are 45% more likely to die from ...

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment. Prostate cancer ...

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...